The 27 references in paper A. ZUDIN M., A. FAIBUSHEVICH G., А. ЗУДИН М., А. ФАЙБУШЕВИЧ Г. (2017) “ОПЫТ ПРИМЕНЕНИЯ ЭНОКСАПАРИНА НАТРИЯ В АМБУЛАТОРНОЙ ПРАКТИКЕ У ПАЦИЕНТОВ С ОККЛЮЗИРУЮЩИМ ТРОМБОЗОМ ГЛУБОКИХ ВЕН // EXPERIENCE IN THE MANAGEMENT OF OCCLUSIVE DEEP VENUS THROMBOSIS WITH ENOXAPARININ SODIUM IN OUTPATIENT SETTINGS” / spz:neicon:aterotromboz:y:2017:i:2:p:13-20

1
Heit JA. The epidemiology of venous thromboembolism in the community. Arterioscler Thromb Vasc Biol, 2008, 28: 370-372.
(check this in PDF content)
2
White RH. The epidemiology of venous thromboembolism. Circulation,2003, 107: I-4-I-8.
(check this in PDF content)
3
Anderson FAJr, Brownell-Wheeler H, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism: the Worcester DVT Study. Arch Int Med,1991, 151: 933-938.
(check this in PDF content)
4
Silverstein MD, Heit JA, Mohr DN et al. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Int Med, 1998, 158:
(check this in PDF content)
5
5-593. 5. Oger E. Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group. Groupe d’Etude de la Thrombose de Bretagne Occidentale. Thromb Haemost, 2000, 83: 657-660.
(check this in PDF content)
6
Eftychiou V. Clinical diagnosis and management of the patient with deep venous thromboembolism and acute pulmonary embolism. Nurse Pract, 1996, 21: 50-52, 58, 61-62, passim, quiz 69-71.
(check this in PDF content)
7
Tapson VF. Acute pulmonary embolism. N Engl J Med, 2008, 358: 1037-1052.
(check this in PDF content)
8
Cohen AT, Agnelli G, Anderson FA et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost, 2007,
(check this in PDF content)
9
756-764. 9. Guidelines on the diagnosis and management of acute pulmonary embolism. The Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J, 2008, 29: 22762315.
(check this in PDF content)
10
Kearon C, Kahn SR, Agnelli G et al. Antithrombotic Therapy for Venous Thromboembolic Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest, 2008, 133(Suppl): 454S-545S.
(check this in PDF content)
11
Cohen M, Demers C, Gurfinkel EP et al. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events Study Group. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med, 1997, 337: 447-452.
(check this in PDF content)
12
Goodman SG, Fitchett D, Armstrong PW et al. Intergrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trail Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation,2003, 107: 238-244.
(check this in PDF content)
13
The SYNERGY Trail Investigators. Enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trail. JAMA,2004, 292: 45-54.
(check this in PDF content)
14
Hylek EM, Regan S, Henault LE et al. Challenges to the effective use of unfractionated heparin in the hospitalized management of acute thrombosis. Arch Intern Med, 2003, 163: 621-627.
(check this in PDF content)
15
Hull RD, Rascob GE, Brant RF et al. Relation between the time to achieve the lower limit of the APTT therapeutic range and recurrent venous thromboembolism during heparin treatment for deep vein thrombosis. Arch Int Med, 1997, 157: 2562-2568.
(check this in PDF content)
16
Hirsh RD, Raschke R, Warkentin T et al. Heparin: mechanism of action, pharmacokinetics, dosing consideration, monitoring, efficacy, and safety. Chest,1995, 108(Suppl): 258S-275S.
(check this in PDF content)
17
Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest, 2001, 119(Suppl): 64S-94S.
(check this in PDF content)
18
Kearon C, Julian JA, Newman TE, Ginsberg JS. Noninvasive diagnosis of deep vein thrombosis. Ann Int Med, 1998, 128: 663-677.
(check this in PDF content)
19
Fihn SD, McDonell M, Martin D et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Ann Int Med,1993, 118: 511-520.
(check this in PDF content)
20
The ACTIVE Writing Group on behalf of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomized controlled trial. Lancet, 2006, 367: 1903-1912.
(check this in PDF content)
21
Lee AY, Levine MN, Baker RI et al. Low-molecular-weight heparin versus a coumarin for prevention of recurrent venous thromboembolism in patient with cancer. N Engl J Med, 2003, 349: 146-153.
(check this in PDF content)
22
Воробьёва Н.М., Панченко Е.П., Кириенко А.И. и др. Варфарин или эноксапарин: что назначить больному венозным тромбозом в первый месяц лечения? Тер. архив, 2009, 81: 57-61.
(check this in PDF content)
23
Heit JA, Mohr DN, Silverstein MD et al. Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. Arch Int Med, 2000, 160: 761-768.
(check this in PDF content)
24
Zhu T, Martinez I, Emmerich J. Venous thromboembolism: risk factors for recurrence. Arterioscler Thromb Vasc Biol, 2009, 29: 298-310.
(check this in PDF content)
25
Christiansen S, Cannegieter SC, Koster T et al. Thrombophilia, clinical factors and recurrent venous thrombotic events. JAMA,2005, 293: 2352-2361.
(check this in PDF content)
26
Hansson PO, SЪrbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Int Med,2000, 160: 769-774.
(check this in PDF content)
27
Baglin T, Palmer CR, Luddington R, Baglin C. Unprovoked recurrent venous thrombosis: prediction by D-dimer and clinical risk factors. J Thromb Haemost,2008, 6: 577-582.
(check this in PDF content)